What is Ultragenyx Pharmaceutical's investment purchases?

Ultragenyx Pharmaceutical (RARE) reported investment purchases of $131M in Q1 2026.

What is the long-term trend for Ultragenyx Pharmaceutical's investment purchases?

Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's investment purchases has grown at a -34.5% compound annual growth rate (CAGR), from $1.01B to $186M.

What does investment purchases mean?

Cash spent purchasing investment securities across all categories.

Ultragenyx Pharmaceutical RARE Investment Purchases

Investment Purchases at other companies

Eli LillyLLY

$297M+50.8%

Ionis PharmaceuticalsIONS

$192.76M-38.0%

Arrowhead ResearchARWR

$924.64M+43.5%

ModernaMRNA

$1.35B-23.6%

Beam TherapeuticsBEAM

$153.79M-54.7%

BridgeBio PharmaBBIO

$52.67M—

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's investment purchases?: Ultragenyx Pharmaceutical (RARE) reported investment purchases of $131M in Q1 2026.
What is the long-term trend for Ultragenyx Pharmaceutical's investment purchases?: Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's investment purchases has grown at a -34.5% compound annual growth rate (CAGR), from $1.01B to $186M.
What does investment purchases mean?: Cash spent purchasing investment securities across all categories.